Physician profile
Daniel K Mckenzie
NPI 1841259066
$1,108.24
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $88.84 · 2021: $351 · 2022: $403 · 2023: $92.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $92.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $92.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $281.15 | 2021-2022 | |
| Pfizer INC. | $239.81 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $156.27 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $53.14 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $45.62 | 2019-2020 | |
| Novo Nordisk INC | $40.79 | 2021 | |
| Amgen INC. | $32.89 | 2020-2023 | Otezla |
| Leo Pharma INC. | $25.67 | 2022 | |
| Janssen Biotech, INC. | $23.47 | 2022 | |
| Allergan, INC. | $23.34 | 2020 | |
| Shield Therapeutics INC | $21.39 | 2023 | Accrufer |
| Gilead Sciences, INC. | $20.50 | 2021 | |
| Ibsa Pharma INC. | $19.75 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.37 | 2022 | |
| Sanofi Pasteur INC. | $18.34 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $17.91 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.55 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.21 | 2019 | |
| Merck Sharp & Dohme LLC | $13.64 | 2022 | |
| Boston Scientific Corporation | $13.61 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.